Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study

Table 3

(a) Computed tomography rest and stress perfusion data measured as attenuation density (AD), perfusion index (PI), and transmural perfusion ratio (TPR). (b) Left ventricle end-diastolic volume (LV EDV), LV thickness, and LV muscle mass for placebo and adipose-derived stromal cell (ASC) group.

(a)

Placebo group

ASC

value (differences between groups for rest values)

value (differences between groups for stress values)

Rest

Stress

Rest

Stress

Baseline

Follow-up

value

Baseline

Follow-up

value

Baseline

Follow-up

value

Baseline

Follow-up

value

AD

92.9 ± 16.0

85.4 ± 16.0

0.132

118.4 ± 17.8

116.1 ± 15.3

0.583

86.2 ± 14.5

86.0 ± 14.7

0.91

118.7 ± 18.0

117.6 ± 20.0

0.675

0.173

0.803

PI

0.20 ± 0.04

0.23 ± 0.13

0.455

0.35 ± 0.05

0.34 ± 0.09

0.792

0.19 ± 0.04

0.19 ± 0.08

0.612

0.33 ± 0.06

0.34 ± 0.07

0.28

0.542

0.419

TPR

1.15 ± 0.13

1.15 ± 0.13

0.959

1.00 ± 0.06

1.05 ± 0.11

0.25

1.15 ± 0.07

1.14 ± 0.10

0.655

1.02 ± 0.06

1.03 ± 0.05

0.733

0.828

0.171

Values are mean ± SD.

(b)

	Placebo			ASC
	Baseline	Follow-up	value	Baseline	Follow-up	value	value (between groups for differences)
LV EDV	127.1 ± 41.9	135.0 ± 41.4	0.203	139.0 ± 40.1	135.0 ± 40.1	0.37	0.126
LV thickness	8.2 ± 2.4	8.5 ± 2.0	0.327	7.8 ± 1.2	8.2 ± 1.7	0.107	0.923
LV muscle mass	151.5 ± 45.8	157.4 ± 56.0	0.214	143.1 ± 34.4	139.6 ± 31.3	0.449	0.199

Values are mean ± SD